Cargando…

抗肿瘤双特异性抗体研究进展与临床研发关注要点

The drugs of programmed cell death 1 and its ligand 1 immune checkpoint inhibitors have ushered in a new era of anti-tumor immunotherapy, which has shown outstanding efficacy in some tumors, such as Hodgkin lymphoma, but there is still low response rate in some kinds of tumors. In recent years, bisp...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549423/
https://www.ncbi.nlm.nih.gov/pubmed/36172734
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.43